Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucagon-like peptide 1 (GLP1) analogues are promising new treatment options for patients with type 2 diabetes, but may have both potentially beneficial and harmful cardiovascular effects. This may also be the case for the analogues of GLP1 for clinical use. The present study examined the effect of treatment with liraglutide, a long-acting GLP1 analogue, on myocardial ischemia and reperfusion in a porcine model. METHODS: Danish Landrace Pigs (70-80 kg) were randomly assigned to liraglutide (10 mug/kg) or control treatment given daily for three days before ischemia-reperfusion. Ischemia was induced by balloon occlusion of the left anterior descending artery for 40 minutes followed by 2.5 hours of reperfusion. The primary outcome parameter was infarct size in relation to the ischemic region at risk. Secondary endpoints were the hemodynamic parameters mean pulmonary pressure, cardiac output, pulmonary capillary wedge pressure as measured by a Swan-Ganz catheter as well as arterial pressure and heart rate. RESULTS: The infarct size in relation to ischemic risk region in the control versus the liraglutide group did not differ significantly: 0.46 +/- 0.14 and 0.54 +/- 0.12) (mean and standard deviation (SD), p = 0.21). Heart rate was significantly higher in the liraglutide group during the experiment, while the other hemodynamic parameters did not differ significantly. CONCLUSION: Liraglutide has a neutral effect on myocardial infarct size in a porcine ischemia-reperfusion model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Previously it has been reported in patients given GLP1 infusion in the reperfusion phase after successful PCI based reperfusion, that ejection fraction (EF) increased in the treated group [16].”
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“Furthermore a recent study in mice reports benefical effects by Liraglutide administration for 7 days before myocardial ischemia [10].”
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 2×
“10 microg/kg was injected subcutaneously once daily based on suggested dose for patients with type 2 DM and resulted in comparable concentration intervals to a previous study in humans [13].”
MethodMyocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy
Bolli, R., Becker, L., Gross, G., Mentzer, R., Balshaw, D., & Lathrop, D. A. (2004) · Circulation Research · doi:10.1161/01.res.0000137171.97172.d7 · Cited by 428
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Nikolaidis, L. A., Doverspike, A., Hentosz, T., Zourelias, L., Shen, Y.-T., Elahi, D., & Shannon, R. P. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073890 · Cited by 137 · cited 1×
“Reports exist evaluating cardiac effects of GLP1 in rodents [5-7] as well as a study in a porcine model giving GLP1 as short-term infusions [8].”
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
Nauck, M. A. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826175 · Cited by 72
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008300 · Cited by 562
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Metadata
- Authors
- Kristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Maeng, M.
- Venue
- BMC Cardiovascular Disorders
- Published
- 2009-07-23
- Volume
- 9
- Issue
- 1
- Pages
- 31-31
- ISSN
- 1471-2261 (ISSN-L)
- OpenAlex
- W2055824736
- Cited by
- 71
- References
- 7
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. https://app.cochat.ai/papers/10.1186/1471-2261-9-31
- The paper
- Kristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Maeng, M. (2009). Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovascular Disorders. https://doi.org/10.1186/1471-2261-9-31
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.